Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3 Lymphoma, Extranodal NK-T-Cell 2 Small Cell Lung Carcinoma 1 Recurrence 1 Radiation Pneumonitis 1 Pleural Effusion, Malignant 1 Neoplasm, Residual 1 NSCLC 1 Lung Neoplasms 1 Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 23 blinatumomab 18 Cytarabine 16 fludarabine 13 Azacitidine 12 venetoclax 10 fludarabine phosphate 10 Rituximab 8 Blood Specimen Collection 8 Methotrexate 7 Lenalidomide 7 Dexamethasone 7 Daunorubicin 7 Mercaptopurine 6 Vincristine 5 daratumumab 4 Whole-Body Irradiation 4 Melphalan 4 Idarubicin 4 Etoposide 4 Drug Therapy 4 Busulfan 4 pembrolizumab 3 obinutuzumab 3 Radiotherapy 3 Neoadjuvant Therapy 3 Maintenance 3 Liquid Biopsy 3 Immunotherapy, Adoptive 3 Imatinib Mesylate 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × sugemalimab × Clear all

NCT05623267 2023-08-07

SURPASS

Sun Yat-sen University

Phase 2/3 Recruiting

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡